Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing.
第一作者:
A,Manni
第一单位:
Department of Translational Biomedicine and Neurosciences (DiBraiN), University of Bari Aldo Moro, Bari, Italy. Electronic address: alessia.manni@uniba.it.
作者:
医学主题词
人类(Humans);克利屈滨(Cladribine);女(雌)性(Female);男(雄)性(Male);成年人(Adult);中年人(Middle Aged);免疫抑制剂(Immunosuppressive Agents);治疗结果(Treatment Outcome);多发性硬化, 复发缓解性(Multiple Sclerosis, Relapsing-Remitting);随访研究(Follow-Up Studies);多发性硬化(Multiple Sclerosis)
DOI
10.1016/j.jns.2024.123070
PMID
38850773
发布时间
2025-08-11
- 浏览0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



